Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kelsey W. Nassar
Observed names:
K. Nassar,
K.W. Nassar,
Kelsey Nassar
Institutions:
University of Colorado Cancer Center,
Cogent Biosciences (United States),
University of Colorado Anschutz
Observed institutions:
University of Colorado Cancer Center,
Cogent Biosciences (United States),
University of Colorado Anschutz,
University of Colorado Denver
ORCID:
0000-0002-2547-7580
Observed ORCID:
0000-0002-2547-7580
OpenAlex ID:
A5005996057
The mutational landscape of mucosal melanoma
2019
·
Kelsey W. Nassar
, Aik Choon Tan
·
Seminars in Cancer Biology
·
247
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
2020
·
Nabanita Mukherjee
, Jenette Skees
, et al.
·
Cell Death and Disease
·
81
PDF
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
2020
·
Carol M. Amato
, Jennifer D. Hintzsche
, et al.
·
Cancers
·
65
PDF
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
2018
·
Thomas C. Beadnell
, Kelsey W. Nassar
, et al.
·
Oncogenesis
·
63
PDF
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
2021
·
Kelsey W. Nassar
, Jennifer D. Hintzsche
, et al.
·
Molecular Cancer Therapeutics
·
38
PDF
AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition
2023
·
Madison M. Rose
, Kelsey W. Nassar
, et al.
·
Medical Oncology
·
2
SF3B1K700E mutation in human embryonic stem cells causes aberrant expression of immune-related genes
2025
·
Mahtab Dastpak
, Claudia A. Mimoso
, et al.
·
PLoS ONE
·
1
PDF
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
2025
·
Aaron C. Smith
, Ben Arwood-Levine
, et al.
·
Cancer Research
·
1
Abstract P4-12-19: Preclinical Characterization of a Novel PI3Kα H1047R Mutant-Selective Inhibitor
2025
·
Aaron C. Smith
, Ben Arwood-Levine
, et al.
·
Clinical Cancer Research
145 (PB133): Preclinical characterization of a novel PI3Kα H1047R mutant-selective inhibitor
2024
·
A.C. Smith
, B. Arwood-Levine
, et al.
·
European Journal of Cancer
Abstract PO3-26-01: Preclinical in vitro and in vivo characterization of a novel, wild-type-sparing, PI3Kα H1047R mutant-selective inhibitor
2024
·
Aaron C. Smith
, Ben Arwood-Levine
, et al.
·
Cancer Research
Data from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
2023
·
Kelsey W. Nassar
, Jennifer D. Hintzsche
, et al.
Supplementary File S1 from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
2023
·
Kelsey W. Nassar
, Jennifer D. Hintzsche
, et al.
Supplementary Tables and Figures from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
2023
·
Kelsey W. Nassar
, Jennifer D. Hintzsche
, et al.
Supplementary Tables and Figures from Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor–Resistant Melanoma
2023
·
Kelsey W. Nassar
, Jennifer D. Hintzsche
, et al.
Chemokine Receptor 1 and its associated immune pathway are downregulated in SF3B1 MT blood and non-blood cancers
2022
·
Mahtab Dastpak
, Hyunmin Kim
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
674 The effective killing of the difficult-to-treat melanomas with the combinations of MCL1 inhibitors S63845/MIK665 plus Navitoclax
2020
·
N. Mukherjee
, J. Skees
, et al.
·
Journal of Investigative Dermatology
Abstract B076: Uncoupling of the cell cycle pathway from the MAPK pathway in BRAF/MEK inhibitor resistant melanoma
2019
·
Kelsey W. Nassar
, Jennifer Hintzsche
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
18
Citation count:
498
H-index:
5
I10-index:
5
Year
Topic
Type